Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development.

Jayawardena N, Poirier JT, Burga LN, Bostina M.

Oncolytic Virother. 2020 Mar 6;9:1-15. doi: 10.2147/OV.S186337. eCollection 2020. Review.


Correction: McCarthy, C.; et al. Developing Picornaviruses for Cancer Therapy. Cancers 2019, 11, 685.

McCarthy C, Jayawardena N, Burga LN, Bostina M.

Cancers (Basel). 2020 Feb 28;12(3). pii: E553. doi: 10.3390/cancers12030553.


Virus-Receptor Interactions: Structural Insights For Oncolytic Virus Development.

Jayawardena N, Burga LN, Poirier JT, Bostina M.

Oncolytic Virother. 2019 Oct 29;8:39-56. doi: 10.2147/OV.S218494. eCollection 2019. Review.


Developing Picornaviruses for Cancer Therapy.

McCarthy C, Jayawardena N, Burga LN, Bostina M.

Cancers (Basel). 2019 May 16;11(5). pii: E685. doi: 10.3390/cancers11050685. Review. Erratum in: Cancers (Basel). 2020 Feb 28;12(3):.


Structural basis for anthrax toxin receptor 1 recognition by Seneca Valley Virus.

Jayawardena N, Burga LN, Easingwood RA, Takizawa Y, Wolf M, Bostina M.

Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10934-E10940. doi: 10.1073/pnas.1810664115. Epub 2018 Oct 31.


Cryo-Electron Microscopy Structure of Seneca Valley Virus Procapsid.

Strauss M, Jayawardena N, Sun E, Easingwood RA, Burga LN, Bostina M.

J Virol. 2018 Feb 26;92(6). pii: e01927-17. doi: 10.1128/JVI.01927-17. Print 2018 Mar 15.


Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus.

Miles LA, Burga LN, Gardner EE, Bostina M, Poirier JT, Rudin CM.

J Clin Invest. 2017 Aug 1;127(8):2957-2967. doi: 10.1172/JCI93472. Epub 2017 Jun 26.


PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells.

Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, DePinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Vander Heiden MG.

Cell. 2013 Oct 10;155(2):397-409. doi: 10.1016/j.cell.2013.09.025.


Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM.

Cancer Discov. 2012 Nov;2(11):1048-63. doi: 10.1158/2159-8290.CD-11-0336. Epub 2012 Aug 22.


Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers.

Burga LN, Tung NM, Troyan SL, Bostina M, Konstantinopoulos PA, Fountzilas H, Spentzos D, Miron A, Yassin YA, Lee BT, Wulf GM.

Cancer Res. 2009 Feb 15;69(4):1273-8. doi: 10.1158/0008-5472.CAN-08-2954. Epub 2009 Feb 3.


Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.

Lam PB, Burga LN, Wu BP, Hofstatter EW, Lu KP, Wulf GM.

Mol Cancer. 2008 Dec 15;7:91. doi: 10.1186/1476-4598-7-91.

Supplemental Content

Loading ...
Support Center